Open Access. Powered by Scholars. Published by Universities.®
- Discipline
-
- Law (3)
- Pharmacy Administration, Policy and Regulation (3)
- Health Law and Policy (2)
- Administrative Law (1)
- Antitrust and Trade Regulation (1)
-
- Bioethics and Medical Ethics (1)
- Biotechnology (1)
- Business (1)
- Clinical Trials (1)
- Cognition and Perception (1)
- Commercial Law (1)
- Food and Drug Law (1)
- Intellectual Property Law (1)
- Life Sciences (1)
- Medical Pharmacology (1)
- Medical Sciences (1)
- Medicinal Chemistry and Pharmaceutics (1)
- Mental and Social Health (1)
- Pharmacoeconomics and Pharmaceutical Economics (1)
- Pharmacology, Toxicology and Environmental Health (1)
- Physical Sciences and Mathematics (1)
- Psychology (1)
- Social and Behavioral Sciences (1)
- Statistics and Probability (1)
- Substance Abuse and Addiction (1)
- Keyword
-
- Drugs (2)
- FDA (2)
- Patients (2)
- Pharmaceutical (2)
- Regulation (2)
-
- Abigail Alliance (1)
- Analysis (1)
- Clinical trials (1)
- Communication (1)
- Doha (1)
- Drug (1)
- Drug makers (1)
- Expert (1)
- GAAT (1)
- Healthcare (1)
- Innovation (1)
- Innovation policy (1)
- Libertarianism (1)
- Manufacturing (1)
- Off-label (1)
- Pain medication (1)
- Patents (1)
- Paternalism (1)
- Pharmaceuticals (1)
- Physicians (1)
- Policy (1)
- Prescription (1)
- Public (1)
- Quality control (1)
- Regulations (1)
- Publication
- Publication Type
Articles 1 - 5 of 5
Full-Text Articles in Pharmaceutical Preparations
Nudging The Fda, W. Nicholson Price Ii, I. Glenn Cohen
Nudging The Fda, W. Nicholson Price Ii, I. Glenn Cohen
Law Faculty Scholarship
[Excerpt] "The FDA’s regulation of drugs is frequently the subject of policy debate, with arguments falling into two camps. On the one hand, a libertarian view of patients and the health care system holds high the value of consumer choice. Patients should get all the information and the drugs they want; the FDA should do what it can to enforce some basic standards but should otherwise get out of the way. On the other hand, a paternalist view values the FDA’s role as an expert agency standing between patients and a set of potentially dangerous drugs and potentially unscrupulous or …
Making Do In Making Drugs: Innovation Policy And Pharmaceutical Manufacturing, W. Nicholson Price Ii
Making Do In Making Drugs: Innovation Policy And Pharmaceutical Manufacturing, W. Nicholson Price Ii
Law Faculty Scholarship
Despite increasing recalls, contamination events, and shortages, drug companies continue to rely on outdated manufacturing plants and processes. Drug manufacturing’s inefficiency and lack of innovation stand in stark contrast to drug discovery, which is the focus of a calibrated innovation policy that combines patents and FDA regulation. Pharmaceutical manufacturing lags far behind the innovative techniques found in other industries due to high regulatory barriers and ineffective intellectual property incentives. Among other challenges, although manufacturers tend to rely on trade secrecy because of the difficulty in enforcing patents on manufacturing processes, trade secrecy provides limited incentives for innovation. To increase those …
An Overview Of Progress In The International Regulation Of The Pharmaceutical Industry, Joan Costa-Font, Aaron Burakoff Harvard University; University Of Barcelona
An Overview Of Progress In The International Regulation Of The Pharmaceutical Industry, Joan Costa-Font, Aaron Burakoff Harvard University; University Of Barcelona
The University of New Hampshire Law Review
[Excerpt] “The pharmaceutical industry, a significant source of healthcare throughout the world, has several features that distinguish it from the rest of the health industry. In the last half-century, new technology, better technological know-how, and overall economic growth have led to widespread and rapid growth in the pharmaceutical sector. Advancements in pharmaceutical research and development have led to the production of drugs that can routinely combat afflictions that, only years ago, were untreatable or even fatal. Since 1970, the average share of Gross Domestic Product (GDP) on pharmaceutical goods has increased in most Organization for Economic Cooperation and Development (OECD) …
Book Review, Jennifer L. Frizzell
Book Review, Jennifer L. Frizzell
RISK: Health, Safety & Environment (1990-2002)
Review of the following: THOMAS SZASZ, OUR RIGHT TO DRUGS: THE CASE FOR A FREE MARKET. (Praeger 1992) [164 pp.] Notes, bibliography, name index, notes, preface, subject index. LC: 91-30378; ISBN: 0-275-94216-3. [Cloth $19.95. P.O. Box 5007, Westwood CT 06881-9990.]
Risk Perception And Drug Safety Evaluation, Ilan B. Vertinsky, Donald A. Wehrung
Risk Perception And Drug Safety Evaluation, Ilan B. Vertinsky, Donald A. Wehrung
RISK: Health, Safety & Environment (1990-2002)
The authors present a Risk communication framework based on a survey of empirical research concerning public Risk perceptions. They also apply it to the area of pharmaceutical regulation to suggest more effective regulatory strategies.